NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.
Plan posted for “public comment” on Dialogue’s Web site; who will respond, Dialogue or NCI? Cost estimate of network significantly reduced.
Also Stillman named director, Cold Spring Harbor, Watson is chancellor.
Pollin Prize honors four pioneers in treatment of childhood leukemia.
December Business & Regulatory Report included in this issue.
The Cancer Letter takes two-week break; next issue Jan. 2.
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time









